The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients | Zendy

Bogdan Balas | Zendy; Muhammad R. Baig | Zendy; Catherine E. Watson | Zendy; Beth E. Dunning | Zendy; Monica LiguerosSaylan | Zendy; Yibin Wang | Zendy; Yan-Ling He | Zendy; Celia Darland | Zendy; Jens J. Holst | Zendy; Carolyn F. Deacon | Zendy; Kenneth Cusi | Zendy; Andrea Mari | Zendy; James E. Foley | Zendy; Ralph A. DeFronzo | Zendy

Open Access

The Dipeptidyl Peptidase IV Inhibitor Vildagliptin Suppresses Endogenous Glucose Production and Enhances Islet Function after Single-Dose Administration in Type 2 Diabetic Patients

Author(s) -

Bogdan Balas,

Muhammad R. Baig,

Catherine E. Watson,

Beth E. Dunning,

Monica LiguerosSaylan,

Yibin Wang,

Yan-Ling He,

Celia Darland,

Jens J. Holst,

Carolyn F. Deacon,

Kenneth Cusi,

Andrea Mari,

James E. Foley,

Ralph A. DeFronzo

Publication year - 2007

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-1882

Subject(s) - vildagliptin , medicine , endocrinology , postprandial , insulin , type 2 diabetes , glucagon like peptide 1 , dipeptidyl peptidase 4 , diabetes mellitus , dipeptidyl peptidase 4 inhibitor , glucagon , chemistry , incretin

Vildagliptin is a selective dipeptidyl peptidase IV inhibitor that augments meal-stimulated levels of biologically active glucagon-like peptide-1. Chronic vildagliptin treatment decreases postprandial glucose levels and reduces hemoglobin A1c in type 2 diabetic patients. However, little is known about the mechanism(s) by which vildagliptin promotes reduction in plasma glucose concentration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research